These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 26100855)

  • 1. Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase.
    Xu L; Zhu H; Hu J; Wu D; Jiang H; Jiang Q; Huang X
    Front Med; 2015 Sep; 9(3):304-11. PubMed ID: 26100855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
    Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
    Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib.
    Breccia M; Palandri F; Iori AP; Colaci E; Latagliata R; Castagnetti F; Torelli GF; Usai S; Valle V; Martinelli G; Rosti G; Foà R; Baccarani M; Alimena G
    Leuk Res; 2010 Feb; 34(2):143-7. PubMed ID: 19481800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis.
    Jiang H; Xu LP; Liu DH; Liu KY; Chen SS; Jiang B; Jiang Q; Chen H; Chen YH; Han W; Zhang XH; Wang Y; Wang JZ; Wang FR; Qin YZ; Lai YY; Huang XJ
    Bone Marrow Transplant; 2014 Sep; 49(9):1146-54. PubMed ID: 25046218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature.
    Ongoren S; Eskazan AE; Suzan V; Savci S; Erdogan Ozunal I; Berk S; Yalniz FF; Elverdi T; Salihoglu A; Erbilgin Y; Iseri SA; Ar MC; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
    Hematology; 2018 May; 23(4):212-220. PubMed ID: 28990873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic Transplantation in Chronic Myeloid Leukemia and the Effect of Tyrosine Kinase Inhibitors on Survival: A Quasi-Experimental Study.
    Özen M; Üstün C; Öztürk B; Topçuoğlu P; Arat M; Gündüz M; Atilla E; Bolat G; Arslan Ö; Demirer T; Akan H; İlhan O; Beksaç M; Gürman G; Özcan M
    Turk J Haematol; 2017 Mar; 34(1):16-26. PubMed ID: 27094579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretransplantation use of the second-generation tyrosine kinase inhibitors has no negative impact on the HCT outcome.
    Piekarska A; Gil L; Prejzner W; Wiśniewski P; Leszczyńska A; Gniot M; Komarnicki M; Hellmann A
    Ann Hematol; 2015 Nov; 94(11):1891-7. PubMed ID: 26220759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The new generation tyrosine kinase inhibitor improves the survival of chronic myeloid leukemia patients after allogeneic stem cell transplantation.
    Shimazu Y; Murata M; Kondo T; Minami Y; Tachibana T; Doki N; Uchida N; Ozawa Y; Yano S; Fukuda T; Kato J; Ara T; Eto T; Ishikawa J; Nakamae H; Tanaka J; Ichinohe T; Atsuta Y; Nagamura-Inoue T;
    Hematol Oncol; 2022 Aug; 40(3):442-456. PubMed ID: 35394658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia.
    Balsat M; Alcazer V; Etienne G; Huguet F; Berger M; Cayssials E; Charbonnier A; Escoffre-Barbe M; Johnson-Ansah H; Legros L; Roy L; Delmer A; Ianotto JC; Orvain C; Larosa F; Meunier M; Amé S; Andreoli A; Cony-Makhoul P; Morisset S; Tigaud I; Rea D; Nicolini FE
    Leuk Res; 2023 Jul; 130():107308. PubMed ID: 37230027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Analysis of the efficacy and influencing factors of nilotinib or dasatinib as second- or third-line treatment in patients with chronic myeloid leukemia in the chronic phase and accelerated phase].
    Yuan T; Lai YY; Qin YZ; Shi HX; Huang XJ; Hou Y; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2020 Feb; 41(2):93-99. PubMed ID: 32135623
    [No Abstract]   [Full Text] [Related]  

  • 11. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase.
    Xiao-Jun H; Lan-Ping X; Kai-Yan L; Dai-Hong L; Huan C; Wei H; Yu-Hong C; Jing-Zhi W; Yao C; Xiao-Hui Z; Hong-Xia S; Dao-Pei L
    Ann Med; 2008; 40(6):444-55. PubMed ID: 18608121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of allogeneic hematopoietic stem cell transplantation in treatment of childhood myelogenous leukemia: the observation of 24 cases].
    Sun Y; Sun RJ; Wei ZJ; Xiao J; Zhang YC; Gao YQ; Zhu HL
    Zhonghua Er Ke Za Zhi; 2012 Nov; 50(11):813-6. PubMed ID: 23302609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic Hematopoietic Stem Cell Transplantation Is an Effective Salvage Therapy for Patients with Chronic Myeloid Leukemia Presenting with Advanced Disease or Failing Treatment with Tyrosine Kinase Inhibitors.
    Nair AP; Barnett MJ; Broady RC; Hogge DE; Song KW; Toze CL; Nantel SH; Power MM; Sutherland HJ; Nevill TJ; Abou Mourad Y; Narayanan S; Gerrie AS; Forrest DL
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1437-44. PubMed ID: 25865648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment efficacy of imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in chronic phase].
    Gao GL; Xu N; Zhou X; Xiao YJ; Ding L; Lu QS; Wei YQ; Zhang Y; Xu D; Sun J; Liu QF; Liu XL
    Zhonghua Yi Xue Za Zhi; 2013 Oct; 93(38):3035-9. PubMed ID: 24417923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of Pretransplant Use of Tyrosine Kinase Inhibitors on Allogeneic Stem Cell Transplantation in Patients with Chronic Myeloid Leukemia - A Single-institution Retrospective Study.
    Fujita S; Kasahara H; Kato J; Koda Y; Shiroshita K; Yamaguchi K; Okayama M; Abe R; Kikuchi T; Shimizu T; Mori T; Kataoka K; Okamoto S
    Intern Med; 2024 Jun; 63(11):1549-1562. PubMed ID: 37899244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors--a single center experience.
    Ribeiro BF; Miranda EC; Albuquerque DM; Delamain MT; Oliveira-Duarte G; Almeida MH; Vergílio B; Silveira RA; Oliveira-Duarte V; Lorand-Metze I; De Souza CA; Pagnano KB
    Clinics (Sao Paulo); 2015 Aug; 70(8):550-5. PubMed ID: 26247667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
    Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
    Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic stem cell transplantation for chronic myeloid leukemia resistant to tyrosine kinase inhibitors.
    Champlin R; Jabbour E; Kebriaei P; Anderlini P; Andersson B; de Lima M
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1(Suppl 1):S96-100. PubMed ID: 22035758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effectiveness of Tyrosine Kinase Inhibitors and Molecular Monitoring Patterns in Newly Diagnosed Patients With Chronic Myeloid Leukemia in the Community Setting.
    Di Bella NJ; Bhowmik D; Bhor M; Yap M; Middlebrook B; Rembert D; Cain Z; Okoro T; Bolinder B; Patt D; Jabbour EJ
    Clin Lymphoma Myeloma Leuk; 2015 Oct; 15(10):599-605. PubMed ID: 26208445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Dasatinib treatment based on BCR- ABL mutation detection in imatinib- resistant patients with chronic myeloid leukemia].
    Jiang Q; Qin Y; Lai Y; Jiang H; Shi H
    Zhonghua Xue Ye Xue Za Zhi; 2016 Jan; 37(1):7-13. PubMed ID: 26876246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.